



June 1, 2017

Immune Design to Present at Jefferies 2017 Global Healthcare Conference

SEATTLE and SOUTH SAN FRANCISCO, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference in New York on Wednesday, June 7, 2017 at 8 a.m. ET.

A live webcast of the presentation will be available online from the investor relations page of the company's corporate website at <http://ir.immunedesign.com/events.cfm>. After the live webcast, an archive of the presentation will be available on the company website for 30 days.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the primary foci of Immune Design's ongoing immunology clinical programs, are products of its two synergistic discovery platforms, ZVex[®] and GLAAS[®]. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.

Media Contact

Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206-769-9219

Investor Contact

Shari Annes
Annes Associates
sannes@annesassociates.com
650-888-0902